今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

真诚的力量：萨日娜谈演艺生涯

资深演员萨日娜：真诚是最好的表演

在演艺圈摸爬滚打15余载的萨日娜，凭借精湛的演技和对角色的深刻理解，塑造了众多令人印象深刻的荧幕形象。近日，她在接受媒体采访时谈及自己的演艺生涯，她表示，真诚是最好的表演。

萨日娜坦言，自己并非科班出身，也没有经过系统的表演训练。但她对表演有着一股天然的热爱，并始终保持着对表演的敬畏之心。她认为，表演不是简单地模仿或演绎，而是要融入角色的内心世界，将角色的喜怒哀乐真情实感地传递给观众。

为了更好地诠释角色，萨日娜往往会深入生活体验人物的感受。在拍摄电视剧《人世间》时，为了演好善良宽厚的周家母亲，她专门去到东北农村体验生活，与当地的老百姓聊家常，感受他们的生活状态。正是这种真诚的态度，让萨日娜塑造的周家母亲得到了观众的一致认可。

除了真诚之外，萨日娜还强调了表演的专业性。她认为，演员需要不断学习和积累，提升自己的表演技巧，才能更好地驾驭不同类型的角色。她自己也十分注重学习，经常阅读剧本、观看电影和电视剧，并向优秀的表演前辈请教。

如今，萨日娜依然活跃在演艺圈，不断挑战新的角色。她表示，希望自己能够不断进步，为观众带来更多优秀的作品。

萨日娜的演艺经历

萨日娜出生于内蒙古，1989年进入演艺圈。她参演过众多影视作品，代表作包括电视剧《人世间》、《情满九道弯》、《闯关东》等。凭借精湛的演技，萨日娜获得了众多奖项，包括第25届中国电视剧金鹰奖最佳女配角奖、第13届华语电影传媒大奖最佳女配角奖等。

萨日娜的表演理念

萨日娜的表演理念可以用“真诚”和“专业”两个词概括。她认为，表演要真诚，要融入角色的内心世界，真情实感地传递给观众。同时，表演也要专业，演员需要不断学习和积累，提升自己的表演技巧。

萨日娜的演艺贡献

萨日娜是一位实力派演员，为中国影视事业做出了重要贡献。她塑造了众多经典荧幕形象，深受观众喜爱。她的表演理念也为年轻演员树立了榜样。